z-logo
open-access-imgOpen Access
DEMOGRAPHIC DETAILS OF COVID-19 CONVALESCENT PLASMA DONORS - AN ANALYSIS.
Author(s) -
Jhalak Patel,
Vishvas Amin
Publication year - 2020
Publication title -
international journal of medical and biomedical studies
Language(s) - English
Resource type - Journals
eISSN - 2589-8698
pISSN - 2589-868X
DOI - 10.32553/ijmbs.v4i9.1429
Subject(s) - convalescent plasma , medicine , antibody , pandemic , outbreak , titer , immunology , covid-19 , virus , virology , disease , infectious disease (medical specialty)
The recent outbreak of severe acute respiratory syndrome corona virus 2 (SARS‐CoV‐2) and subsequent corona virus disease 2019 (COVID‐19) has created a global health emergency with unparalleled worldwide burden. Passive immunity delivered as anti‐corona virus antibodies from convalescent human plasma may offer a novel therapeutic approach for COVID‐19. Aim: The aim of this study is to understand this pandemic and its association to demographic pattern of convalescent plasma donors if any which can help us to find a possible solution to fight against this pandemic. Materials and method: This is a retrospective study carried out at Ahmedabad Red Cross from a period of April 2020 to September 2020. The donors are scrutinized on the basis of Age-group, Blood Group, gender and Positive Antibody IgG titre index. Result: Among 288 COVID-19 Plasma donor accepted for plasma donation; 278 were males and 7 were females. Majority of the donors belong to age group of 22-27 years of age. B positive blood group was most common encountered in the study. Most donors had SAR-COV-2 antibody titre in range of 2-4. Conclusion: In this pandemic convalescent plasma therapy is used on compassionate basis in moderately ill patients and demographic studies help us to know the pattern of infectivity and can help us bring permanent treatment for the same. Keywords: Convalescent plasma, blood group, IgG-antibody titre

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here